Polymorphic variants of MRP4/ABCC4 differentially modulate the transport of methylated arsenic metabolites and physiological organic anions.

[1]  X. Le,et al.  Methylated and thiolated arsenic species for environmental and health research - A review on synthesis and characterization. , 2016, Journal of environmental sciences.

[2]  S. Cole,et al.  Cysteinyl Leukotriene Receptor 1/2 Antagonists Nonselectively Modulate Organic Anion Transport by Multidrug Resistance Proteins (MRP1-4) , 2016, Drug Metabolism and Disposition.

[3]  J. Hulot,et al.  MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease. , 2016, Pharmacological research.

[4]  J. Fletcher,et al.  ABC transporters as mediators of drug resistance and contributors to cancer cell biology. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[5]  G. Conseil,et al.  N-linked glycans do not affect plasma membrane localization of multidrug resistance protein 4 (MRP4) but selectively alter its prostaglandin E2 transport activity. , 2016, Biochemical and biophysical research communications.

[6]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[7]  Wei Zhang,et al.  The Pharmacological and Physiological Role of Multidrug-Resistant Protein 4 , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[8]  X Chris Le,et al.  Characterization of arsenic hepatobiliary transport using sandwich-cultured human hepatocytes. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[9]  W. Goessler,et al.  Genetic Variation in Arsenic (+3 Oxidation State) Methyltransferase (AS3MT), Arsenic Metabolism and Risk of Basal Cell Carcinoma in a European Population , 2014, Environmental and molecular mutagenesis.

[10]  X. Le,et al.  A Novel Pathway for Arsenic Elimination: Human Multidrug Resistance Protein 4 (MRP4/ABCC4) Mediates Cellular Export of Dimethylarsinic Acid (DMAV) and the Diglutathione Conjugate of Monomethylarsonous Acid (MMAIII) , 2014, Molecular Pharmacology.

[11]  B. Rosen,et al.  Aquaglyceroporins: generalized metalloid channels. , 2014, Biochimica et biophysica acta.

[12]  W. Cullen.  Chemical mechanism of arsenic biomethylation. , 2014, Chemical research in toxicology.

[13]  S. Cole,et al.  Two Polymorphic Variants of ABCC1 Selectively Alter Drug Resistance and Inhibitor Sensitivity of the Multidrug and Organic Anion Transporter Multidrug Resistance Protein 1 , 2013, Drug Metabolism and Disposition.

[14]  X. Chris Le,et al.  Arsenic Binding to Proteins , 2013, Chemical reviews.

[15]  R. Altman,et al.  Collective judgment predicts disease-associated single nucleotide variants , 2013, BMC Genomics.

[16]  H. Ostergaard,et al.  Enhanced Immunogenicity of a Tricomponent Mannan Tetanus Toxoid Conjugate Vaccine Targeted to Dendritic Cells via Dectin-1 by Incorporating β-Glucan , 2013, The Journal of Immunology.

[17]  D. Budman,et al.  The evolving use of arsenic in pharmacotherapy of malignant disease , 2013, Annals of Hematology.

[18]  Habibul Ahsan,et al.  The Broad Scope of Health Effects from Chronic Arsenic Exposure: Update on a Worldwide Public Health Problem , 2013, Environmental health perspectives.

[19]  I. Adzhubei,et al.  Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.

[20]  S. Cole,et al.  Mutation of Glu521 or Glu535 in Cytoplasmic Loop 5 Causes Differential Misfolding in Multiple Domains of Multidrug and Organic Anion Transporter MRP1 (ABCC1)* , 2012, The Journal of Biological Chemistry.

[21]  X. Le,et al.  Monomethylarsenic Diglutathione Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1) , 2011, Drug Metabolism and Disposition.

[22]  S. Cole,et al.  Mammalian multidrug-resistance proteins (MRPs). , 2011, Essays in biochemistry.

[23]  T. Agusa,et al.  Individual Variations in Inorganic Arsenic Metabolism Associated with AS3MT Genetic Polymorphisms , 2011, International journal of molecular sciences.

[24]  R. Villa-Bellosta,et al.  Arsenate transport by sodium/phosphate cotransporter type IIb. , 2010, Toxicology and applied pharmacology.

[25]  E. Leslie,et al.  Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. , 2010, Carcinogenesis.

[26]  B. Ganguli,et al.  Comparison of drinking water, raw rice and cooking of rice as arsenic exposure routes in three contrasting areas of West Bengal, India , 2010, Environmental geochemistry and health.

[27]  A. Andoh,et al.  The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease , 2010, Journal of Gastroenterology.

[28]  M. Krajinovic,et al.  Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. , 2009, Blood.

[29]  S. Cole,et al.  Molecular Basis for Reduced Estrone Sulfate Transport and Altered Modulator Sensitivity of Transmembrane Helix (TM) 6 and TM17 Mutants of Multidrug Resistance Protein 1 (ABCC1) , 2009, Drug Metabolism and Disposition.

[30]  S. Cole,et al.  Multiple Roles of Charged Amino Acids in Cytoplasmic Loop 7 for Expression and Function of the Multidrug and Organic Anion Transporter MRP1 (ABCC1) , 2009, Molecular Pharmacology.

[31]  E. Krieger,et al.  Functional Role of Arginine 375 in Transmembrane Helix 6 of Multidrug Resistance Protein 4 (MRP4/ABCC4) , 2008, Molecular Pharmacology.

[32]  Pritha Ghosh,et al.  Toxicogenomics of arsenic: classical ideas and recent advances. , 2008, Mutation research.

[33]  M. Relling,et al.  Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. , 2008, Cancer research.

[34]  A. Ravna,et al.  Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4). , 2008, Bioorganic & medicinal chemistry letters.

[35]  S. Cole,et al.  Down-regulation of Na+/H+ exchanger regulatory factor 1 increases expression and function of multidrug resistance protein 4. , 2008, Cancer research.

[36]  Conrad C. Huang,et al.  The Human Multidrug Resistance Protein 4 (MRP4, ABCC4): Functional Analysis of a Highly Polymorphic Gene , 2008, Journal of Pharmacology and Experimental Therapeutics.

[37]  M. Fromm,et al.  6‐mercaptopurine and 9‐(2‐phosphonyl‐methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4 , 2008, Human mutation.

[38]  L. M. Hodges,et al.  Substrate-Dependent Effects of Human ABCB1 Coding Polymorphisms , 2008, Journal of Pharmacology and Experimental Therapeutics.

[39]  S. Cole,et al.  Role of proline 1150 in functional interactions between the membrane spanning domains and nucleotide binding domains of the MRP1 (ABCC1) transporter. , 2008, Biochemical pharmacology.

[40]  Rosalinde Masereeuw,et al.  Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. , 2008, Trends in pharmacological sciences.

[41]  R. Marcos,et al.  Evaluation of micronucleus frequencies in blood lymphocytes from smelting plant workers exposed to arsenic , 2008, Environmental and molecular mutagenesis.

[42]  H. Glaeser,et al.  Variability in human hepatic MRP4 expression: influence of cholestasis and genotype , 2008, The Pharmacogenomics Journal.

[43]  Paul B Watkins,et al.  Differential Inhibition of Rat and Human Na+-Dependent Taurocholate Cotransporting Polypeptide (NTCP/SLC10A1)by Bosentan: A Mechanism for Species Differences in Hepatotoxicity , 2007, Journal of Pharmacology and Experimental Therapeutics.

[44]  C. Tseng,et al.  Arsenic Methylation, Urinary Arsenic Metabolites and Human Diseases: Current Perspective , 2007, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[45]  S. Waxman,et al.  Disruption of cAMP and Prostaglandin E2 Transport by Multidrug Resistance Protein 4 Deficiency Alters cAMP-Mediated Signaling and Nociceptive Response , 2007, Molecular Pharmacology.

[46]  Thomas J. Smith,et al.  Arsenic Methylation, GSTT1, GSTM1, GSTP1 Polymorphisms, and Skin Lesions , 2006, Environmental health perspectives.

[47]  M. Banerjee,et al.  Polymorphism in the ERCC2 codon 751 is associated with arsenic-induced premalignant hyperkeratosis and significant chromosome aberrations. , 2006, Carcinogenesis.

[48]  R. Dawson,et al.  Structure of a bacterial multidrug ABC transporter , 2006, Nature.

[49]  Pritha Ghosh,et al.  Cytogenetic damage and genetic variants in the individuals susceptible to arsenic‐induced cancer through drinking water , 2006, International journal of cancer.

[50]  S. Cole,et al.  Identification of Proline Residues in the Core Cytoplasmic and Transmembrane Regions of Multidrug Resistance Protein 1 (MRP1/ABCC1) Important for Transport Function, Substrate Specificity, and Nucleotide Interactions* , 2004, Journal of Biological Chemistry.

[51]  D. Keppler,et al.  Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane , 2003, Hepatology.

[52]  J. Wijnholds,et al.  The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Uchiumi,et al.  Trafficking and functional defects by mutations of the ATP‐binding domains in MRP2 in patients with Dubin‐Johnson syndrome , 2002, Hepatology.

[54]  M. Lieberman,et al.  The MRP2/cMOAT Transporter and Arsenic-Glutathione Complex Formation Are Required for Biliary Excretion of Arsenic* , 2000, The Journal of Biological Chemistry.

[55]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[56]  J. Marshall,et al.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.

[57]  J. Kalivas.  Evaluation of volume and matrix effects for the generalized standard addition method. , 1987, Talanta.

[58]  A. Fulton,et al.  Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. , 2015, Prostaglandins & other lipid mediators.

[59]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[60]  A. Lilienfeld,et al.  Cancer and occupational exposure to arsenic: a study of pesticide workers. , 1980, Preventive medicine.